Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: PawPr who wrote (647)	4/10/1998 3:54:00 PM
From: SG	Read Replies (2) \| Respond to of 965

Where was there a mention of possible association with lymphoma for Avakine? SG

To: PawPr who wrote (647)	4/14/1998 2:27:00 AM
From: FNS	Respond to of 965

Check out the Merk thread. Much info (from post #692): <<A FDA advisory panel on Friday recommended Aggrasat for use in combination with the blood thinner heparin and aspirin to prevent heart attacks in patients with unstable angina and non-Q-wave myocardial infarction, also known as acute coronary syndrome. But the panel declined to vote on whether to recommend use of the drug for patients undergoing angioplasties to prevent heart attack, repeat procedures and abrupt artery closure. Angioplasties are procedures in which a balloon is inserted into clogged arteries to dilate the blood vessels and thereby improve blood circulation. The FDA's Cardiovascular and Renal Drugs Advisory Committee said it wanted to defer to the FDA on the angioplasty indication. Everen Securities analyst Jeffrey Kraws said he believed the FDA, which usually follows the recommendations of its advisory panels, will likely approve Aggrastat for both indications.>> ................. Does anyone have any comment on impact to reopro? I would imagine that CNTO will have to change sales forecast figures to reflect potential of competitive drugs! FNS